Holger N Lode

List of Publications by Year
in descending order

50 papers	1,859 citations	331670 21 h-index	265206 42 g-index
51 all docs	51 docs citations	51 times ranked	2120 citing authors

#	Article	IF	Citations
1	Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. Lancet Oncology, The, 2018, 19, 1617-1629.	10.7	252
2	Natural Killer Cellâ€“Mediated Eradication of Neuroblastoma Metastases to Bone Marrow by Targeted Interleukin-2 Therapy. Blood, 1998, 91, 1706-1715.	1.4	171
3	NK cells engineered to express a GD₂â€specific antigen receptor display builtâ€in ADCCâ€like activity against tumour cells of neuroectodermal origin. Journal of Cellular and Molecular Medicine, 2012, 16, 569-581.	3.6	163
4	Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. Molecular Immunology, 2005, 42, 1311-1319.	2.2	99
5	Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1). Cancers, 2020, 12, 309.	3.7	84
6	EZH2 Inhibition in Ewing Sarcoma Upregulates GD2 Expression for Targeting with Gene-Modified T Cells. Molecular Therapy, 2019, 27, 933-946.	8.2	69
7	Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients. MAbs, 2013, 5, 801-809.	5.2	66
8	Characterization of GD2 Peptide Mimotope DNA Vaccines Effective against Spontaneous Neuroblastoma Metastases. Cancer Research, 2006, 66, 10567-10575.	0.9	63
9	Survivin minigene DNA vaccination is effective against neuroblastoma. International Journal of Cancer, 2009, 125, 104-114.	5.1	63
10	Fractalkine (CX3CL1)â€“ and Interleukin-2â€“Enriched Neuroblastoma Microenvironment Induces Eradication of Metastases Mediated by T Cells and Natural Killer Cells. Cancer Research, 2007, 67, 2331-2338.	0.9	62
11	Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD₂ antibody ch14.18/CHO. MAbs, 2018, 10, 55-61.	5.2	57
12	Salmonella SL7207 application is the most effective DNA vaccine delivery method for successful tumor eradication in a murine model for neuroblastoma. Cancer Letters, 2013, 331, 167-173.	7.2	53
13	PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD₂ antibody ch14.18/CHO. OncoImmunology, 2017, 6, e1343775.	4.6	53
14	Targeted Cytokines for Cancer Immunotherapy. Immunologic Research, 2000, 21, 279-288.	2.9	49
15	Vaccination with anti-idiotype antibody ganglidiomab mediates a GD2-specific anti-neuroblastoma immune response. Cancer Immunology, Immunotherapy, 2013, 62, 999-1010.	4.2	44
16	Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2. MAbs, 2016, 8, 604-616.	5.2	43
17	Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survival. OncoImmunology, 2016, 5, e1235108.	4.6	39
18	Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma. Cancer Immunology, Immunotherapy, 2015, 64, 621-634.	4.2	38

#	Article	IF	Citations
19	A rationally designed tyrosine hydroxylase DNA vaccine induces specific antineuroblastoma immunity. Molecular Cancer Therapeutics, 2008, 7, 2241-2251.	4.1	35
20	Nivolumab and dinutuximab beta in two patients with refractory neuroblastoma. , 2020, 8, e000540.		33
21	Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells. Oncotarget, 2017, 8, 16605-16620.	1.8	30
22	Functional Bioassays for Immune Monitoring of High-Risk Neuroblastoma Patients Treated with ch14.18/CHO Anti-GD2 Antibody. PLoS ONE, 2014, 9, e107692.	2.5	25
23	Xenogeneic immunization with human tyrosine hydroxylase DNA vaccines suppresses growth of established neuroblastoma. Molecular Cancer Therapeutics, 2009, 8, 2392-2401.	4.1	23
24	GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD2 and Releasing Inducible IL-18. Frontiers in Immunology, 2022, 13, 839783.	4.8	20
25	Randomization of dose-reduced subcutaneous interleukin-2 (scIL2) in maintenance immunotherapy (IT) with anti-GD₂ antibody dinutuximab beta (DB) long-term infusion (LTI) in frontâ€“line high-risk neuroblastoma patients: Early results from the HR-NBL1/SIOPEN trial.. Journal of Clinical Oncology, 2019, 37, 10013-10013.	1.6	19
26	GD2 targeting by dinutuximab beta is a promising immunotherapeutic approach against malignant glioma. Journal of Neuro-Oncology, 2020, 147, 577-585.	2.9	18
27	Targeting of MYCN by means of DNA vaccination is effective against neuroblastoma in mice. Cancer Immunology, Immunotherapy, 2015, 64, 1215-1227.	4.2	17
28	Inflammatory response and treatment tolerance of longâ€term infusion of the antiâ€GD₂ antibody ch14.18/CHO in combination with interleukinâ€2 in patients with highâ€risk neuroblastoma. Pediatric Blood and Cancer, 2018, 65, e26967.	1.5	15
29	Low CD4â¹/CD25â¹/CD127â» regulatory T cell- and high INF-Î³ levels are associated with improved survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2. OncoImmunology, 2019, 8, 1661194.	4.6	14
30	Randomized use of anti-GD₂ antibody dinutuximab beta (DB) long-term infusion with and without subcutaneous interleukin-2 (scIL-2) in high-risk neuroblastoma patients with relapsed and refractory disease: Results from the SIOPEN LTI-trial.. Journal of Clinical Oncology, 2019, 37, 10014-10014.	1.6	14
31	Validated detection of human anti-chimeric immune responses in serum of neuroblastoma patients treated with ch14.18/CHO. Journal of Immunological Methods, 2014, 407, 108-115.	1.4	13
32	Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial. Cancers, 2018, 10, 387.	3.7	13
33	Validated detection of anti-GD2 antibody ch14.18/CHO in serum of neuroblastoma patients using anti-idiotype antibody ganglidiomab. Journal of Immunological Methods, 2013, 398-399, 51-59.	1.4	12
34	Generation and Characterization of a Human/Mouse Chimeric GD2-Mimicking Anti-Idiotype Antibody Ganglidiximab for Active Immunotherapy against Neuroblastoma. PLoS ONE, 2016, 11, e0150479.	2.5	12
35	DNA Minigene Vaccination for Adjuvant Neuroblastoma Therapy. Annals of the New York Academy of Sciences, 2004, 1028, 113-121.	3.8	11
36	GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma. , 2021, 9, e002923.		11

#	Article	IF	Citations
37	Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment. Frontiers in Immunology, 2021, 12, 690467.	4.8	10
38	Nutrient mixture including vitamin C, L-lysine, L-proline, and epigallocatechin is ineffective against tumor growth and metastasis in a syngeneic neuroblastoma model. Pediatric Blood and Cancer, 2008, 50, 284-288.	1.5	7
39	Reduction of CD11b ⁺ myeloid suppressive cells augments anti-neuroblastoma immune response induced by the anti-GD ₂ antibody ch14.18/CHO. OncoImmunology, 2020, 9, 1836768.	4.6	6
40	Immunotherapy with anti-GD2 antibody ch14.18/CHOÂ±IL2 within the HR-NBL1/SIOPEN trial to improve outcome of high-risk neuroblastoma patients compared to historical controls.. Journal of Clinical Oncology, 2018, 36, 10539-10539.	1.6	6
41	Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy. Frontiers in Pediatrics, 2020, 8, 582820.	1.9	6
42	Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials. Cancers, 2022, 14, 1919.	3.7	6
43	Co-expression of IL-15 enhances anti-neuroblastoma effectivity of a tyrosine hydroxylase-directed DNA vaccination in mice. PLoS ONE, 2018, 13, e0207320.	2.5	5
44	MYCN-targeting vaccines and immunotherapeutics. Human Vaccines and Immunotherapeutics, 2016, 12, 2257-2258.	3.3	4
45	First-line Anti-GD2 Therapy Combined With Consolidation Chemotherapy in 3 Patients With Newly Diagnosed Metastatic Ewing Sarcoma or Ewing-like Sarcoma. Journal of Pediatric Hematology/Oncology, 2022, 44, e948-e953.	0.6	4
46	Neuroblastoma with intracerebral metastases and the need for neurosurgery: a single-center experience. Journal of Neurosurgery: Pediatrics, 2020, 25, 51-56.	1.3	2
47	Approaches to Passive and Active Vaccination against Neuroblastoma. Pediatric and Adolescent Medicine, 0, , 150-162.	0.4	0
48	Neuroblastom. Springer Reference Medizin, 2021, , 1-14.	0.0	0
49	MDR-1 Recognition by Cytotoxic T Cells.. Blood, 2004, 104, 1346-1346.	1.4	0
50	Effective Induction of Apoptosis by Mistletoe Plant Extracts in an Acute Lymphoblastic Leukemia Model.. Blood, 2006, 108, 1880-1880.	1.4	0